KRYS

Krystal Biotech, Inc.

Krystal Biotech, Inc. is a pivotal-stage gene therapy company leveraging its novel, redosable gene therapy platform and in-house manufacturing capabilities to develop therapies to treat serious rare diseases.

Krystal Biotech, Inc. (KRYS) is scored daily on Deltasharpe Prism against Healthcare sector peers across five pillars: Value, Growth, Profitability, Momentum and Revisions.

Quantitative Factor Evaluation • Updated

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-16 C (2.3) C (2.4) B+ (3.8) B (3.2) C+ (2.8) B- (2.9)
2026-11-09 C (2.2) C (2.4) B+ (3.7) B- (3.1) C+ (2.8) B- (2.9)
2026-11-03 C- (2.1) C+ (2.6) B+ (3.8) B+ (3.5) C+ (2.8) B- (3.0)
2026-11-02 C- (2.1) C+ (2.6) B+ (3.8) B (3.3) D+ (1.7) C+ (2.7)
2026-10-27 C (2.2) C+ (2.6) B+ (3.8) B- (3.1) D+ (1.7) C+ (2.7)
Page 1 of 2

Showing the last month only. Subscribe for the full factor score history.

For more — Subscribe